Results 51 to 60 of about 13,967 (254)

Histamine H3 Receptor Antagonists Go to Clinics

open access: yesBiological and Pharmaceutical Bulletin, 2008
Within the recent years novel lead optimisations for histamine H(3) receptor antagonists made their way from bench to bedside. Structure-activity relationships, cross-affinities and side effects as well as pharmacokinetic profiling will be discussed on selected promising compound series.
Kerstin, Sander   +2 more
openaire   +3 more sources

Therapeutic Approach of Histamine H3 Receptors in Obesity [PDF]

open access: yesRecent Patents on CNS Drug Discovery, 2007
Obesity is considered one of the risk factors for metabolic disorders. There is increasing evidence that obesity is under control of several cytokines and hormone in the brain. Brain histamine and H3 receptors are important factors for regulating obesity.
Takayuki, Masaki, Hironobu, Yoshimatsu
openaire   +2 more sources

Transient changes in the limbic histaminergic system after systemic kainic acid-induced seizures

open access: yesNeurobiology of Disease, 2005
Increased brain histamine is reported to protect against convulsions. We used systemic kainic acid (KA) administration to study possible changes of the histaminergic system in rat brain in status epilepticus (SE).
Minnamaija Lintunen   +3 more
doaj   +1 more source

Novel H3 receptor antagonists. Sulfonamide homologs of histamine

open access: greenBioorganic & Medicinal Chemistry Letters, 1998
Sulfonamides derived from 4(5)-(omega-aminoalkyl)-1H-imidazoles containing chain lengths of three- to five-carbons were synthesized. Good to moderate H3 receptor binding affinities were observed for several butyl and pentyl homologs, whereas binding affinities were considerably weaker in the propyl series.
Ronald Wolin   +7 more
openalex   +3 more sources

The Histamine H3 Receptor: Structure, Pharmacology, and Function [PDF]

open access: yesMolecular Pharmacology, 2016
Among the four G protein-coupled receptors (H1-H4) identified as mediators of the biologic effects of histamine, the H3 receptor (H3R) is distinguished for its almost exclusive expression in the nervous system and the large variety of isoforms generated by alternative splicing of the corresponding mRNA.
Gustavo, Nieto-Alamilla   +4 more
openaire   +2 more sources

Blocking Histamine H1 Improves Learning and Mnemonic Dysfunction in Mice With Social Isolation Plus Repeated Methamphetamine Injection

open access: yesJournal of Pharmacological Sciences, 2008
The aim of this study was to investigate the effects of histamine H1 and H3 antagonists on learning and mnemonic dysfunction in mice. Two H1 antagonists, pyrilamine and clozapine, and the prototypic H3 antagonist thioperamide were used to study the role ...
Feiyong Jia   +9 more
doaj   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian   +3 more
wiley   +1 more source

Histamine H3 Heteroreceptors Suppress Glutamatergic and GABAergic Synaptic Transmission in the Rat Insular Cortex

open access: yesFrontiers in Neural Circuits, 2017
Histamine H3 receptors are autoreceptors that regulate histamine release from histaminergic neuronal terminals. The cerebral cortex, including the insular cortex (IC), expresses abundant H3 receptors; however, the functions and mechanisms of H3 receptors
Hiroki Takei   +8 more
doaj   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen   +2 more
wiley   +1 more source

Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies [PDF]

open access: yes, 2016
Support was kindly provided by the EU COST Action CM1103. DA, KN, and JV kindly acknowledge national project number 172033 and OI1612039 supported by the Ministry of the Republic of Serbia.
Agbaba, Danica   +7 more
core   +3 more sources

Home - About - Disclaimer - Privacy